New Advances in Chemical Research in 2021. In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 89891-65-6, name is 7-Bromo-2-chloroquinoxaline, introducing its new discovery. Recommanded Product: 7-Bromo-2-chloroquinoxaline
In the recent years, PI3Kdelta has emerged as a promising target for the treatment of B- and T-cell mediated inflammatory diseases. We present a cellular assay activity analysis for our previously reported 4,6-diaryl quinazoline PI3Kdelta inhibitor series that suggests an optimal logP range between 2 and 3. We discovered novel analogues in this lipophilicity space that feature a chiral pyrrolidineoxy-group as a replacement for the position-4 aromatic ring of 4,6-diaryl quinazolines. These Fsp3enriched derivatives retain potency and selectivity towards PI3Kdelta. Compared to 4,6-diaryl quinazolines, their permeability profile is improved and molecular weight as well as PSA are reduced. These modifications offer additional possibilities for derivative generation in a favorable physicochemical property space and thus increase the chances to identify a clinical candidate.
If you are interested in 89891-65-6, you can contact me at any time and look forward to more communication. Recommanded Product: 7-Bromo-2-chloroquinoxaline
Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1975 | ChemSpider